GO
Loading...

Enter multiple symbols separated by commas

Life Sciences

More

  • Eli Lilly and Cree are big market movers Thursday, 25 Jun 2015 | 4:46 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:. Eli Lilly and Co., up $2.54 to $84.80. Lindsay Corp., up $7.08 to $89.70.

  • Bristol-Myers Squibb to shift research jobs Thursday, 25 Jun 2015 | 10:59 AM ET

    HARTFORD, Conn.— Bristol-Myers Squibb Co. will expand its presence in research centers in Cambridge, Massachusetts, and San Francisco, as it cuts jobs in Connecticut, the biopharmaceutical company announced Thursday. The New York- based company will open a research site in Cambridge— home to the Massachusetts Institute of Technology and Harvard— in 2018 and...

  • June 22- Cancer drug developers Kite Pharma Inc and Bluebird Bio Inc said they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers. The National Cancer Institute has indicated that cell therapies could eventually become the standard of care in the multi-billion market to treat cancer. Juno Therapeutics Inc, another...

  • *Guinea trial last chance to show vaccine efficacy. LONDON, June 17- Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa. The haemorrhagic Ebola virus has killed more than 11,000 people in Guinea, Sierra Leone and Liberia in an...

  • *Company to meet FDA to discuss regulatory path. June 15- RedHill Biopharma Ltd said its experimental drug met the main goal of eradicating a bacterial infection in a late-stage study, sending its shares up as much as 35 percent to a record high. Ascendiant Capital Market's Edward Woo said the drug is one of RedHill's biggest opportunities and could rake in peak...

  • June 15- RedHill Biopharma Ltd said its experimental antibiotic drug met the main goal in a late-stage study, sending the Israeli drugmaker's U.S.-listed shares up 19.6 pct in premarket trading.

  • LONDON, June 13- A pioneering gene therapy for sickle cell disease is working well so far for a 13- year-old French boy with the hereditary blood disorder, researchers said on Saturday, in a boost for the technology to fix faulty genes. He is the first patient with severe sickle cell disease to be treated with Bluebird Bio's LentiGlobin BB305 product, which the U.S....

  • SHANGHAI, June 12- The World Health Organization has approved a Chinese influenza vaccine as being safe and effective, only the second Chinese vaccine to receive such status reflecting the growing clout of the country's drug makers. The WHO said in a statement on Friday that it had "prequalified" a vaccine made by Hualan Biological Bacterin Corp, a subsidiary of...

  • The USDA has been developing a vaccine against bird flu and was weighing whether to release it to drug makers for widespread production. Turkey producers in Minnesota, where nearly 9 million birds have been affected by the disease since the beginning of the year, had asked the USDA to approve use of a vaccine to help prevent further infections.

  • Could virus make the leap from birds to people? Saturday, 30 May 2015 | 12:02 PM ET
    Lacey Kurth, a research associate, works with avian influenza test samples during testing in the real-time analytical diagnostics lab at the Iowa State University College of Veterinary Medicine in Ames, Iowa.

    There have only been four flu pandemics since the start of the 20th century, yet concerns are widening about the potential for a new outbreak.

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • May 21- Biotech firm Bluebird Bio Inc said its experimental gene therapy continued to exhibit a positive effect in an ongoing early-stage study of patients with rare types of blood disorders. The product, LentiGlobin, is being tested in patients with beta-thalassemia major and those with severe sickle cell disease, two hereditary conditions.

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Drugmaker Alexion Pharmaceuticals Inc agreed to buy Synageva BioPharma Corp for $8.4 billion at a hefty premium to expand in the lucrative market for drugs that treat rare diseases. The drug, whose marketing application is being reviewed in the United States and Europe, treats a rare and...

  • Two pharma giants merge in $8.4B deal Wednesday, 6 May 2015 | 8:01 AM ET
    Pharmaceuticals

    Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.

  • May 6- Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to boost its rare drug pipeline. Kanuma's marketing application is being reviewed in the United States and Europe. Recent deals involving rare disease companies include Teva Pharmaceutical Industries Inc's $3.5 billion purchase of Auspex...

  • Alexion Pharma to buy Synageva BioPharma for $8.4 bln Wednesday, 6 May 2015 | 6:54 AM ET

    May 6- Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease. Alexion's cash-and-stock offer values Synageva at $225.92 per share, representing a premium of 135.7 percent to the stock's close on Tuesday. The deal is expected to...

  • May 4- Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop...